Jump to content

NONMEM: Difference between revisions

From Wikipedia, the free encyclopedia
Content deleted Content added
m References: replace/remove deprecated cs1|2 parameters; using AWB
Updated product site URL
Tag: Possible vandalism
Line 12: Line 12:


==External links==
==External links==
*[http://www.iconplc.com/technology/products/nonmem/ Product site]
*[http://www.iconplc.com/innovation/solutions/nonmem/ Product site]
*[http://www.cognigencorp.com/index.php/cognigen/resources_nonmem NONMEM UsersNet Archive]
*[http://www.cognigencorp.com/index.php/cognigen/resources_nonmem NONMEM UsersNet Archive]



Revision as of 11:51, 6 June 2016

NONMEM is a software package developed by Stuart L. Beal and Lewis B. Sheiner in the late 1970s at UCSF for population pharmacokinetic modeling.[1][2][3][4] Its name is an acronym for non-linear mixed effects modeling and has become the "gold standard"[citation needed], both in the pharmaceutical industry and academia.

References

  1. ^ Sheiner, Lewis B.; B. Rosenberg; V.V. Marathe (1977). "Evaluation of Methods for Estimating Population Pharmacokinetic Parameters I. Michaelis-Menten Model: Routine Clinical Pharmacokinetic Data". Journal of Pharmacokinetics and Biopharmaceutics. 5 (5): 445–79. doi:10.1007/BF01061728. PMID 925881.
  2. ^ Sheiner, Lewis B.; Stuart L. Beal (1980). "Evaluation of Methods for Estimating Population Pharmacokinetic Parameters I. Michaelis-Menten Model: Routine Clinical Pharmacokinetic Data". Journal of Pharmacokinetics and Biopharmaceutics. 8 (6): 553–71. doi:10.1007/BF01060053.
  3. ^ Sheiner, Lewis B.; Stuart L. Beal (1981). "Evaluation of Methods for Estimating Population Pharmacokinetic Parameters II. Biexponential Model and Experimental Pharmacokinetic Data". Journal of Pharmacokinetics and Biopharmaceutics. 9 (5): 635–51. doi:10.1007/BF01061030.
  4. ^ Sheiner, Lewis B.; Stuart L. Beal (1983). "Evaluation of Methods for Estimating Population Pharmacokinetic Parameters III. Monoexponential Model: Routine Clinical Pharmacokinetic Data". Journal of Pharmacokinetics and Biopharmaceutics. 11 (3): 303–19. doi:10.1007/BF01061870.